431 related articles for article (PubMed ID: 17854398)
1. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease.
Maloney B; Ge YW; Alley GM; Lahiri DK
J Neurochem; 2007 Nov; 103(3):1237-57. PubMed ID: 17854398
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease.
Lahiri DK; Sambamurti K; Bennett DA
Neurobiol Aging; 2004; 25(5):651-60. PubMed ID: 15172744
[TBL] [Abstract][Full Text] [Related]
3. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.
Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW
Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457
[TBL] [Abstract][Full Text] [Related]
4. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.
Dodart JC; Marr RA; Koistinaho M; Gregersen BM; Malkani S; Verma IM; Paul SM
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1211-6. PubMed ID: 15657137
[TBL] [Abstract][Full Text] [Related]
5. NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells.
Du Y; Chen X; Wei X; Bales KR; Berg DT; Paul SM; Farlow MR; Maloney B; Ge YW; Lahiri DK
Brain Res Mol Brain Res; 2005 May; 136(1-2):177-88. PubMed ID: 15893602
[TBL] [Abstract][Full Text] [Related]
6. A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease.
Licastro F; Veglia F; Chiappelli M; Grimaldi LM; Masliah E
Neurobiol Aging; 2004 Sep; 25(8):1017-22. PubMed ID: 15212826
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region.
Ge YW; Ghosh C; Song W; Maloney B; Lahiri DK
J Neurochem; 2004 Sep; 90(6):1432-44. PubMed ID: 15341527
[TBL] [Abstract][Full Text] [Related]
8. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E.
Laws SM; Hone E; Taddei K; Harper C; Dean B; McClean C; Masters C; Lautenschlager N; Gandy SE; Martins RN
Mol Psychiatry; 2002; 7(8):886-90. PubMed ID: 12232782
[TBL] [Abstract][Full Text] [Related]
9. APOE promoter polymorphisms do not confer independent risk for Alzheimer's disease in a French population.
Zurutuza L; Verpillat P; Raux G; Hannequin D; Puel M; Belliard S; Michon A; Pothin Y; Camuzat A; Penet C; Martin C; Brice A; Campion D; Clerget-Darpoux F; Frebourg T
Eur J Hum Genet; 2000 Sep; 8(9):713-6. PubMed ID: 10980578
[TBL] [Abstract][Full Text] [Related]
10. Promoter polymorphism in fibroblast growth factor 1 gene increases risk of definite Alzheimer's disease.
Yamagata H; Chen Y; Akatsu H; Kamino K; Ito J; Yokoyama S; Yamamoto T; Kosaka K; Miki T; Kondo I
Biochem Biophys Res Commun; 2004 Aug; 321(2):320-3. PubMed ID: 15358178
[TBL] [Abstract][Full Text] [Related]
11. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model.
Mann KM; Thorngate FE; Katoh-Fukui Y; Hamanaka H; Williams DL; Fujita S; Lamb BT
Hum Mol Genet; 2004 Sep; 13(17):1959-68. PubMed ID: 15229191
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease.
Bullido MJ; Valdivieso F
Microsc Res Tech; 2000 Aug; 50(4):261-7. PubMed ID: 10936877
[TBL] [Abstract][Full Text] [Related]
13. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD.
Riazanskaia N; Lukiw WJ; Grigorenko A; Korovaitseva G; Dvoryanchikov G; Moliaka Y; Nicolaou M; Farrer L; Bazan NG; Rogaev E
Mol Psychiatry; 2002; 7(8):891-8. PubMed ID: 12232783
[TBL] [Abstract][Full Text] [Related]
14. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression.
Borroni B; Archetti S; Costanzi C; Grassi M; Ferrari M; Radeghieri A; Caimi L; Caltagirone C; Di Luca M; Padovani A;
Neurobiol Aging; 2009 Sep; 30(9):1406-12. PubMed ID: 18179845
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional significance of polymorphisms in the mu-opioid receptor gene (Oprm) promoter of C57BL/6 and DBA/2 mice.
Doyle GA; Sheng XR; Schwebel CL; Ferraro TN; Berrettini WH; Buono RJ
Neurosci Res; 2006 Jul; 55(3):244-54. PubMed ID: 16644048
[TBL] [Abstract][Full Text] [Related]
16. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation.
Licastro F; Porcellini E; Caruso C; Lio D; Corder EH
Neurobiol Aging; 2007 Nov; 28(11):1637-43. PubMed ID: 16930778
[TBL] [Abstract][Full Text] [Related]
17. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
18. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes.
Bray NJ; Jehu L; Moskvina V; Buxbaum JD; Dracheva S; Haroutunian V; Williams J; Buckland PR; Owen MJ; O'Donovan MC
Hum Mol Genet; 2004 Nov; 13(22):2885-92. PubMed ID: 15385439
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease.
Yu JT; Tan L; Song JH; Sun YP; Chen W; Miao D; Tian Y
Brain Res; 2009 Feb; 1253():169-75. PubMed ID: 19073159
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of APOE and LRP genes in Brazilian individuals with Alzheimer disease.
Bahia VS; Kok F; Marie SN; Shinjo SO; Caramelli P; Nitrini R
Alzheimer Dis Assoc Disord; 2008; 22(1):61-5. PubMed ID: 18317248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
